The University of Southampton
University of Southampton Institutional Repository

Cleavage-independent HIV-1 trimers from CHO cell lines elicit robust autologous tier 2 neutralizing antibodies

Cleavage-independent HIV-1 trimers from CHO cell lines elicit robust autologous tier 2 neutralizing antibodies
Cleavage-independent HIV-1 trimers from CHO cell lines elicit robust autologous tier 2 neutralizing antibodies

Native flexibly linked (NFL) HIV-1 envelope glycoprotein (Env) trimers are cleavage-independent and display a native-like, well-folded conformation that preferentially displays broadly neutralizing determinants. The NFL platform simplifies large-scale production of Env by eliminating the need to co-transfect the precursor-cleaving protease, furin that is required by the cleavage-dependent SOSIP trimers. Here, we report the development of a CHO-M cell line that expressed BG505 NFL trimers at a high level of homogeneity and yields of ~1.8 g/l. BG505 NFL trimers purified by single-step lectin-affinity chromatography displayed a native-like closed structure, efficient recognition by trimer-preferring bNAbs, no recognition by non-neutralizing CD4 binding site-directed and V3-directed antibodies, long-term stability, and proper N-glycan processing. Following negative-selection, formulation in ISCOMATRIX adjuvant and inoculation into rabbits, the trimers rapidly elicited potent autologous tier 2 neutralizing antibodies. These antibodies targeted the N-glycan "hole" naturally present on the BG505 Env proximal to residues at positions 230, 241, and 289. The BG505 NFL trimers that did not expose V3 in vitro, elicited low-to-no tier 1 virus neutralization in vivo, indicating that they remained intact during the immunization process, not exposing V3. In addition, BG505 NFL and BG505 SOSIP trimers expressed from 293F cells, when formulated in Adjuplex adjuvant, elicited equivalent BG505 tier 2 autologous neutralizing titers. These titers were lower in potency when compared to the titers elicited by CHO-M cell derived trimers. In addition, increased neutralization of tier 1 viruses was detected. Taken together, these data indicate that both adjuvant and cell-type expression can affect the elicitation of tier 2 and tier 1 neutralizing responses in vivo.

Adjuvants, HIV-1, Immunogenicity, Immunologic, Recombinant protein expression, Vaccines, Viral fusion proteins
1664-3224
Bale, Shridhar
2b36dee6-de09-4f14-93ee-36675753434a
Martiné, Alexandra
69206821-a13d-4601-b0dd-d391a023ee1c
Wilson, Richard
fcd03016-c8b4-42f8-aa50-00a7aef1c5d7
Behrens, Anna Janina
ed584c40-79cb-4de9-bb9c-bd68c71d6a68
Fourn, Valérie Le
a08931af-7d0f-4f22-8e5f-686c7b70de80
Val, Natalia de
17ca4fc8-dfab-41dc-aa68-26de0e9a265c
Sharma, Shailendra K.
c73f4d28-22e3-4308-a2f0-51c9f7094e27
Tran, Karen
eaa16679-ad01-4332-9456-363ad9597890
Torres, Jonathan L.
8e9a3e7b-a841-4748-927b-967ac8135774
Girod, Pierre Alain
0fc64b4f-a1a9-48dc-9b3c-d5c34b0af777
Ward, Andrew B.
78ce5b6a-b852-4ee4-a950-f7ff7b183d83
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Wyatt, Richard T.
39dd4553-50f2-4221-a527-c80d64defc8c
Bale, Shridhar
2b36dee6-de09-4f14-93ee-36675753434a
Martiné, Alexandra
69206821-a13d-4601-b0dd-d391a023ee1c
Wilson, Richard
fcd03016-c8b4-42f8-aa50-00a7aef1c5d7
Behrens, Anna Janina
ed584c40-79cb-4de9-bb9c-bd68c71d6a68
Fourn, Valérie Le
a08931af-7d0f-4f22-8e5f-686c7b70de80
Val, Natalia de
17ca4fc8-dfab-41dc-aa68-26de0e9a265c
Sharma, Shailendra K.
c73f4d28-22e3-4308-a2f0-51c9f7094e27
Tran, Karen
eaa16679-ad01-4332-9456-363ad9597890
Torres, Jonathan L.
8e9a3e7b-a841-4748-927b-967ac8135774
Girod, Pierre Alain
0fc64b4f-a1a9-48dc-9b3c-d5c34b0af777
Ward, Andrew B.
78ce5b6a-b852-4ee4-a950-f7ff7b183d83
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Wyatt, Richard T.
39dd4553-50f2-4221-a527-c80d64defc8c

Bale, Shridhar, Martiné, Alexandra, Wilson, Richard, Behrens, Anna Janina, Fourn, Valérie Le, Val, Natalia de, Sharma, Shailendra K., Tran, Karen, Torres, Jonathan L., Girod, Pierre Alain, Ward, Andrew B., Crispin, Max and Wyatt, Richard T. (2018) Cleavage-independent HIV-1 trimers from CHO cell lines elicit robust autologous tier 2 neutralizing antibodies. Frontiers in Immunology, 9 (MAY). (doi:10.3389/fimmu.2018.01116).

Record type: Article

Abstract

Native flexibly linked (NFL) HIV-1 envelope glycoprotein (Env) trimers are cleavage-independent and display a native-like, well-folded conformation that preferentially displays broadly neutralizing determinants. The NFL platform simplifies large-scale production of Env by eliminating the need to co-transfect the precursor-cleaving protease, furin that is required by the cleavage-dependent SOSIP trimers. Here, we report the development of a CHO-M cell line that expressed BG505 NFL trimers at a high level of homogeneity and yields of ~1.8 g/l. BG505 NFL trimers purified by single-step lectin-affinity chromatography displayed a native-like closed structure, efficient recognition by trimer-preferring bNAbs, no recognition by non-neutralizing CD4 binding site-directed and V3-directed antibodies, long-term stability, and proper N-glycan processing. Following negative-selection, formulation in ISCOMATRIX adjuvant and inoculation into rabbits, the trimers rapidly elicited potent autologous tier 2 neutralizing antibodies. These antibodies targeted the N-glycan "hole" naturally present on the BG505 Env proximal to residues at positions 230, 241, and 289. The BG505 NFL trimers that did not expose V3 in vitro, elicited low-to-no tier 1 virus neutralization in vivo, indicating that they remained intact during the immunization process, not exposing V3. In addition, BG505 NFL and BG505 SOSIP trimers expressed from 293F cells, when formulated in Adjuplex adjuvant, elicited equivalent BG505 tier 2 autologous neutralizing titers. These titers were lower in potency when compared to the titers elicited by CHO-M cell derived trimers. In addition, increased neutralization of tier 1 viruses was detected. Taken together, these data indicate that both adjuvant and cell-type expression can affect the elicitation of tier 2 and tier 1 neutralizing responses in vivo.

Text
fimmu-09-01116 - Version of Record
Available under License Creative Commons Attribution.
Download (5MB)

More information

Accepted/In Press date: 3 May 2018
e-pub ahead of print date: 24 May 2018
Keywords: Adjuvants, HIV-1, Immunogenicity, Immunologic, Recombinant protein expression, Vaccines, Viral fusion proteins

Identifiers

Local EPrints ID: 421520
URI: https://eprints.soton.ac.uk/id/eprint/421520
ISSN: 1664-3224
PURE UUID: 49365cbc-408d-4713-a1f7-83c921885839
ORCID for Max Crispin: ORCID iD orcid.org/0000-0002-1072-2694

Catalogue record

Date deposited: 14 Jun 2018 16:30
Last modified: 14 Mar 2019 01:25

Export record

Altmetrics

Contributors

Author: Shridhar Bale
Author: Alexandra Martiné
Author: Richard Wilson
Author: Anna Janina Behrens
Author: Valérie Le Fourn
Author: Natalia de Val
Author: Shailendra K. Sharma
Author: Karen Tran
Author: Jonathan L. Torres
Author: Pierre Alain Girod
Author: Andrew B. Ward
Author: Max Crispin ORCID iD
Author: Richard T. Wyatt

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×